Obesity Is Associated With the Development of Interstitial Pneumonia Under Long-Term Administration of Amiodarone in Refractory Atrial Fibrillation Patients
-
- Koike Hideki
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Fujino Tadashi
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Koike Makiko
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Shinohara Masaya
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Kitahara Ken
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Kinoshita Toshio
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Yuzawa Hitomi
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Suzuki Takeya
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Sato Hideyuki
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Fukunaga Shunji
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Kobayashi Kenzaburo
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Ikeda Takanori
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
書誌事項
- 公開日
- 2016
- 資源種別
- journal article
- DOI
-
- 10.1536/ihj.15-276
- 公開者
- 一般社団法人 インターナショナル・ハート・ジャーナル刊行会
この論文をさがす
説明
Although oral amiodarone (AMD) has been used for the management of atrial fibrillation (AF), serious complications such as interstitial pneumonia (IP) occur very occasionally. We evaluated which factors were associated with the development of IP under the long-term administration of AMD in patients with refractory AF.<br>This study included 122 consecutive patients (65.8 ± 11.4 years, mean body mass index [BMI] of 23.2 ± 4.3 kg/m2) who orally received AMD to inhibit AF between January 2004 and December 2013. Administration of AMD was begun at 400 mg daily as a loading dose, and was continued at a dosage of 50-400 mg daily after the initial loading phase, determined by the control of the arrhythmias and occurrence of side-effects. The clinical factors were compared between the patients with and without adverse effects, especially IP.<br>During an average follow-up period of 49.2 ± 28.2 months, 53 patients (43.4%) were determined to have converted and maintained sinus rhythm. In contrast, adverse effects were detected in 46 patients (37.7%) with AMD. IP occurred in 8 patients (6.6%), thyrotoxicosis in 35 (28.7%), and others in 5 (4.1%). Four (50.0%) out of 8 patients complicated with IP had obesity (BMI > 27 kg/m2). Among the clinical factors, only obesity was significantly associated with the development of IP (P = 0.026).<br>In patients with refractory AF, AMD had an antiarrhythmic effect with long-term administration, but greater adverse effects were also observed. Obesity was the most significant factor associated with the development of IP.
収録刊行物
-
- International Heart Journal
-
International Heart Journal 57 (1), 30-34, 2016
一般社団法人 インターナショナル・ハート・ジャーナル刊行会
